Sep 10, 2025
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Sep 04, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceVIEW RELEASE
Aug 27, 2025
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®VIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Sep 16, 2025 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
2.99
CHANGE
-0.18 (0%)
